BR100 Increased By (0.63%)
BR30 Increased By (0.45%)
KSE100 Increased By (0.8%)
KSE30 Increased By (0.71%)
AGHA 6.07 Increased By ▲ 0.05 (0.83%)
BECO 3.89 Increased By ▲ 0.08 (2.1%)
BML 61.73 Increased By ▲ 5.29 (9.37%)
BOP 28.20 Increased By ▲ 0.10 (0.36%)
CNERGY 11.91 Decreased By ▼ -0.37 (-3.01%)
CSIL 5.37 Increased By ▲ 0.08 (1.51%)
FCCL 54.25 Increased By ▲ 0.44 (0.82%)
FFL 12.90 Increased By ▲ 0.10 (0.78%)
FNEL 1.13 Increased By ▲ 0.01 (0.89%)
KEL 5.65 Increased By ▲ 0.01 (0.18%)
KOSM 5.35 Decreased By ▼ -0.03 (-0.56%)
LOTCHEM 23.79 Increased By ▲ 0.24 (1.02%)
MLCF 93.00 Increased By ▲ 1.04 (1.13%)
NBP 163.51 Increased By ▲ 1.27 (0.78%)
NCPL 48.81 Decreased By ▼ -0.10 (-0.2%)
NPL 50.20 Decreased By ▼ -0.31 (-0.61%)
OGDC 303.00 Increased By ▲ 1.32 (0.44%)
PACE 9.13 No Change ▼ 0.00 (0%)
PAEL 31.98 Increased By ▲ 0.17 (0.53%)
PIBTL 12.83 Increased By ▲ 0.05 (0.39%)
PPL 212.10 Increased By ▲ 0.04 (0.02%)
PRL 84.34 Decreased By ▼ -2.92 (-3.35%)
PTC 44.99 Increased By ▲ 1.03 (2.34%)
SSGC 22.88 Increased By ▲ 0.02 (0.09%)
TBL 8.97 Increased By ▲ 0.06 (0.67%)
TELE 6.50 Increased By ▲ 0.06 (0.93%)
TPL 24.23 Increased By ▲ 0.14 (0.58%)
TPLP 12.25 Increased By ▲ 0.09 (0.74%)
TREET 23.39 Decreased By ▼ -0.11 (-0.47%)
TRG 51.80 Decreased By ▼ -0.07 (-0.13%)
World

Benefits of J&J COVID-19 vaccine outweigh possible risks

  • "Together with the European Medicines Authority we are monitoring the situation very closely", the CBG said. "For now, the benefits of the vaccine outweigh the possible risks."
Published Updated
By

AMSTERDAM: The Dutch medicines regulator (CBG) on Tuesday said the benefits of the Johnson & Johnson COVID-19 vaccine outweigh the possible risks, after US federal health agencies recommended pausing the use of the shot.

"Together with the European Medicines Authority we are monitoring the situation very closely", the CBG said. "For now, the benefits of the vaccine outweigh the possible risks."

The US agencies made their recommendation after six recipients developed a rare disorder involving blood clots.

Comments

Comments are closed for this article.